We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+32.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.65B
AUM Growth
+$1.82B
Cap. Flow
+$94.6M
Cap. Flow %
0.98%
Top 10 Hldgs %
77.89%
Holding
99
New
5
Increased
16
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$37.7M
3
IMVT icon
Immunovant
IMVT
+$22.4M
4
BCAX
Bicara Therapeutics
BCAX
+$21.3M
5
SMMT icon
Summit Therapeutics
SMMT
+$16.8M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$28M
2
LONA
LeonaBio Inc
LONA
+$8.36M
3
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$4.4M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$2.28M
5
SAGE
Sage Therapeutics
SAGE
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 98.95%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
1
BeOne Medicines Ltd
ONC
$33.8B
$2.37B 24.59%
10,568,897
– –
INCY icon
2
Incyte
INCY
$25.5B
$2.03B 21.06%
30,739,020
+496
+0% +$31.6K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.43B
$659M 6.83%
42,877,916
– –
SMMT icon
4
Summit Therapeutics
SMMT
$9.86B
$535M 5.54%
24,424,865
+1,202,643
+5% +$16.8M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.5B
$419M 4.34%
1,974,590
– –
RVMD icon
6
Revolution Medicines
RVMD
$38.2B
$343M 3.56%
7,569,090
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.3B
$335M 3.47%
6,398,366
+1
+0% +$48
INSM icon
8
Insmed
INSM
$22.6B
$322M 3.34%
4,415,918
+839,880
+23% +$62M
KYMR icon
9
Kymera Therapeutics
KYMR
$8.59B
$284M 2.94%
5,995,929
+1
+0% +$44
BCYC
10
Bicycle Therapeutics
BCYC
$269M
$213M 2.2%
9,399,960
– –
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.27B
$156M 1.62%
5,840,059
– –
REPL icon
12
Replimune Group
REPL
$413M
$121M 1.25%
11,045,336
+1,000,000
+10% +$10.2M
ALKS icon
13
Alkermes
ALKS
$8.22B
$117M 1.21%
4,181,751
– –
DNLI icon
14
Denali Therapeutics
DNLI
$3.76B
$109M 1.13%
3,731,695
– –
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.51B
$87.6M 0.91%
1,576,114
+109,567
+7% +$5.58M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.43B
$87.2M 0.9%
3,882,125
– –
TRDA icon
17
Entrada Therapeutics
TRDA
$229M
$77.8M 0.81%
4,865,819
– –
IMTX icon
18
Immatics
IMTX
$1.16B
$73.5M 0.76%
6,443,398
– –
ABCL icon
19
AbCellera Biologics
ABCL
$1.62B
$71.6M 0.74%
27,525,640
– –
KNSA icon
20
Kiniksa Pharmaceuticals
KNSA
$6.13B
$70.4M 0.73%
2,818,323
– –
IGMS
21
DELISTED
IGM Biosciences
IGMS
$67.7M 0.7%
4,092,310
+1,994
+0% +$21.8K
ARGX icon
22
argenx
ARGX
$55B
$60.7M 0.63%
111,904
– –
STOK icon
23
Stoke Therapeutics
STOK
$1.81B
$53.7M 0.56%
4,368,443
– –
IMCR icon
24
Immunocore
IMCR
$1.68B
$47.2M 0.49%
1,515,318
– –
KOD icon
25
Kodiak Sciences
KOD
$2.4B
$45.2M 0.47%
17,310,490
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Baker Bros. Advisors held 99 positions worth $9.65B, up 23% from $7.83B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Baker Bros. Advisors's Q3 2024 filing shows 5 new, 16 increased, 3 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 833,333 shares worth $21.2M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2024 buy was Bicara Therapeutics: 833,333 shares worth $21.2M.
  • Baker Bros. Advisors added most to Insmed in Q3 2024, an estimated $62M increase.
  • Baker Bros. Advisors's biggest Q3 2024 reduction was NewAmsterdam Pharma, cutting an estimated $2.01K.
  • Baker Bros. Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $28M.
  • Baker Bros. Advisors's ten largest holdings make up 78% of its $9.65B portfolio in Q3 2024.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q3 2024.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.65B.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.